有关物质 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
=== 22 SAS Regiment === Since serving in Malaya, men from the regular army 22 SAS Regiment have taken part in reconnaissance patrols and large scale raiding missions in the Jebel Akhdar War in Oman and conducted covert reconnaissance and surveillance patrols and some larger scale raiding missions in Borneo during the Indonesia–Malaysia confrontation. They returned to Oman in operations against Communist-backed rebels in the Dhofar Rebellion including the Battle of Mirbat. They have also taken part in operations in the Aden Emergency, Northern Ireland, and Gambia. Their Special projects team assisted the West German counterterrorism group GSG 9 at Mogadishu, with Lufthansa Flight 181. The SAS counter terrorist wing famously took part in a hostage rescue operation during the Iranian Embassy Siege in London. SAS were involved throughout Britain's covert involvement in the Soviet–Afghan War; they acted through private military contractor Keenie Meenie Services (or KMS Ltd), training the Afghan Mujaheddin in weapons, tactics and using explosives. They trained the Mujaheddin in Afghanistan and sent them to be trained in Pakistan, Oman and parts of the UK. During the Falklands War B squadron were prepared for Operation Mikado before it was subsequently cancelled while D and G squadrons were deployed and participated in the raid on Pebble Island. Operation Flavius was a controversial operation in Gibraltar against the Provisional Irish Republican Army (PIRA). 22 SAS directed NATO aircraft onto Serb positions and hunted war criminals in Bosnia.
This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a quinone or similar compound as acceptor. The systematic name of this enzyme class is glutathione:dehydroascorbate oxidoreductase. Other names in common use include dehydroascorbic reductase, dehydroascorbic acid reductase, glutathione dehydroascorbate reductase, DHA reductase, dehydroascorbate reductase, GDOR, and glutathione:dehydroascorbic acid oxidoreductase. This enzyme participates in three metabolic pathways: ascorbate and aldarate metabolism, glutamate metabolism, and glutathione metabolism.
==== MeSH E05.196.630 – microchip analytical procedures ==== MeSH E05.196.630.465 – microfluidic analytical techniques MeSH E05.196.630.465.340 – electrophoresis, microchip MeSH E05.196.630.570 – microarray analysis MeSH E05.196.630.570.660 – oligonucleotide array sequence analysis MeSH E05.196.630.570.700 – protein array analysis MeSH E05.196.630.570.850 – tissue array analysis
Sources: en.wikipedia.org
Difficulty staying awake Mental confusion Impaired motor functions Impaired reflexes Impaired coordination Impaired balance Dizziness Respiratory depression Low blood pressure Coma Death Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a four-year-old boy who overdosed on clonazepam. The combination of clonazepam and certain barbiturates (for example, amobarbital), at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression. Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.
== Early years == Rodrigo Roa Duterte was born on March 28, 1945, in Maasin, Leyte. His father was Vicente Gonzales Duterte (1911–1968), a Cebuano lawyer, and his mother, Soledad Gonzales Roa (1916–2012), was a schoolteacher from Cabadbaran, Agusan and a civic leader, of Chinese and Spanish mestizo descent. Duterte has said that his grandfather was Chinese and hailed from Xiamen in Fujian, China. Duterte has four siblings: Eleanor (born 1941/42), Emmanuel, Jocelyn (1948–2023) and Benjamin ("Bong", 1953–2026). Duterte's father was mayor of Danao, Cebu, and subsequently the provincial governor of (the then-undivided) Davao province. Rodrigo's cousin Ronald was mayor of Cebu City from 1983 to 1986. Ronald's father, Ramon Duterte, also held that position from 1957 to 1959. The Dutertes consider the Cebu-based political families of the Durano and the Almendras clan as relatives. Duterte also has relatives from the Roa clan in Leyte through his mother's side. Duterte's family lived in Maasin, and in his father's hometown in Danao, until he was four years old. Duterte was heavily influenced by his mother, who unlike Vicente was a staunch anti-Marcos activist, which led the young Duterte to have a divided opinion on the Marcoses. Duterte later said Marcos could have been the best president, but he was a dictator. The Dutertes initially moved to Mindanao in 1948 but still went back and forth to the Visayas until 1949. They finally settled in the Davao Region in 1950. Vicente worked as a lawyer engaged in private practice.
== Office closures == In August 2026, TikTok announced plans to close its Nashville, Tennessee, office, with the closure scheduled for October 5, 2026. The decision will affect approximately 250 employees, according to a notice filed with the Tennessee Department of Labor and Workforce Development. The Nashville location had included members of TikTok's content moderation operations. The company said the closure was intended to reorganize its U.S. operations and bring teams into closer alignment with its long-term plans.
=== For Alzheimer's disease === Several companies are in the early stages of development and testing of this potential class of treatment. In March 2008 phase I results were reported for CoMentis Inc's candidate CTS-21166. In April 2012 Merck & Co., Inc reported phase I results for its candidate verubecestat (MK-8931). Merck began a Phase II/III trial of MK-8931 in December, 2012 estimated to be completed in July 2019. In February 2017, Merck halted its late-stage trial of verubecestat for mild to moderate Alzheimer's disease after it was reported as having "virtually no chance" of working according to an independent panel of experts. This came just three months after Eli Lilly & Co. announced its own setback with solanezumab. In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop lanabecestat (AZD3293). A pivotal Phase II/III clinical trial of lanabecestat started in late 2014, but was halted in 2018 before its planned conclusion due to poor results. Another BACE1 inhibitor that has reached phase II trials is the Eli Lilly's inhibitor LY2886721. The data on phase I trial were first presented at the Alzheimer's Association International conference in 2012. Daily dosing during 2 weeks, reduced BACE1 activity by 50–75% and CSF Aβ42 by 72% (Willis et al., 2012; Bowman Rogers and Strobel, 2013). Recently, Lilly reported that the phase II trial of LY2886721 was terminated due to liver abnormalities that were found in 4 out of 45 patients (Rogers, 2013).
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。